Lei Zhang, MD
Chinese Academy of Medical Science and Blood Disease Hospital
Emerging Leaders
not ranked
Current Leaders
#3942 pts
All-Time Leaders
#20136 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2018. 18 trials as lead/chair. How it works →
Trials led — by scientific impact
Clinical Exploration of Clinical Exploration Adeno-associated Virus Vector Expression of Human Coagulation Factor VIII Gene Therapy for Hemophilia A
N/ARecruitingInstitute of Hematology & Blood Diseases Hospital, China
10
impact
A Multicenter Single-arm Study to Evaluate the Efficacy and Safety of Eltrombopag for Immune Thrombocytopenia in Chinese Patients With Chronic HBV Infection
Phase 2CompletedInstitute of Hematology & Blood Diseases Hospital, China
5
impact
Study of Human Umbilical Cord-derived Mesenchymal Stem Cells for Treatment of Refractory Immune Thrombocytopenia
N/ACompletedInstitute of Hematology & Blood Diseases Hospital, China
5
impact
Evaluation of Immune Status Before and After Splenectomy in Immune Thrombocytopenia Patients
N/ARecruitingInstitute of Hematology & Blood Diseases Hospital, China
4
impact
Prospective, Single Arm and Open Clinical Observation of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia
Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China
4
impact
Safety and Efficacy of Zanubrutinib in the Treatment of Immune Thrombocytopenia
Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China
3
impact
A Prospective, One-arm and Open Clinical Study to Assess Safety and Efficacy of Anti-Human CD38 Monoclonal Antibody CM313 in the Treatment of Primary Immune Thrombocytopenia
Phase 2CompletedInstitute of Hematology & Blood Diseases Hospital, China
2
impact
Avatrombopag for Chemotherapy-induced Thrombocytopenia in Solid Tumors: a Prospective Multi-center One-arm Study
Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China
1
impact
A Prospective, One-arm and Open Clinical Study to Assess Safety and Efficacy of Anti-CD38 Antibody in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia
Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China
1
impact
A Prospective, One-arm and Open Clinical Study to Assess Safety and Efficacy of Nicotinamide Adenine Dinucleotide in the Treatment of Primary Immune Thrombocytopenia
Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China
1
impact
An Open, Exploratory Clinical Study to Assess Safety and Efficacy of BCMA-CD3 Bispecific Antibody CM336 in the Treatment of Primary Immune Thrombocytopenia
Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China
1
impact
A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study to Assess Safety and Efficacy of Anti-Human CD38 Monoclonal Antibody CM313 in the Treatment of Primary Immune Thrombocytopenia
Phase 2ActiveInstitute of Hematology & Blood Diseases Hospital, China
0
impact
A Single-arm, Open-label Clinical Study Evaluating the Safety and Efficacy of Daratumumab in Elderly Patients With Primary Immune Thrombocytopenia
Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China
0
impact
A Prospective, One-arm and Open Clinical Study to Assess Safety and Efficacy of Anti-CD38 Antibody in the Treatment of Children With Primary Immune Thrombocytopenia
Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China
0
impact
A Prospective, One-arm and Open Clinical Study to Assess Safety and Efficacy of Anti-Human CD20 Monoclonal Antibody Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia
Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China
0
impact
Clinical Characteristics, Prognosis and Prognostic Model of Pediatric Immune Thrombocytopenia: a Prospective, Multicenter, Observational Cohort Study
N/ARecruitingInstitute of Hematology & Blood Diseases Hospital, China
0
impact
The Outcome Comparison of Immune Tolerance Induction Therapy Using SCT800 Combined With Daratumumab or SCT800 Alone in Hemophilia A Adolescents and Adults With High Titer Inhibitor: a Non-randomized Controlled Trial
Phase 4RecruitingInstitute of Hematology & Blood Diseases Hospital, China
0
impact
A Multicenter, Single-arm Exploratory Study of CD38 (Daratumumab) Monoclonal Antibody (Daratumumab) Combined Corticosteroid in the Treatment of Acquired Hemophilia A (AHA)
Phase 4RecruitingInstitute of Hematology & Blood Diseases Hospital, China
0
impact
A Prospective, One-arm and Open Clinical Study to Assess Safety and Efficacy of Anti-CD38 Antibody in the Treatment of Pediatric Primary Immune Thrombocytopenia
Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China
0
impact
A Prospective, One-arm and Open Clinical Study to Assess Safety and Efficacy of Anti-Human CD20 Monoclonal Antibody Obinutuzumab in the Treatment of Primary Immune Thrombocytopenia
Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China
0
impact
Herombopag for Chemotherapy-induced Thrombocytopenia: a Prospective Multi-center One-arm Study in Solid Tumors
Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China
0
impact